發(fā)布時(shí)間：2018-03-09 14:59

  本文選題：急性白血病　切入點(diǎn)：CD34　出處：《寧夏醫(yī)科大學(xué)》2012年碩士論文　論文類型：學(xué)位論文

【摘要】：目的探討CD34抗原在小兒急性白血病（AL）中的表達(dá)與臨床表現(xiàn)及化療療效的關(guān)系。 方法采用流式細(xì)胞術(shù)分別檢測(cè)85例急性淋巴細(xì)胞白血�。ˋLL）及42例急性髓系白血�。ˋML）初診患兒骨髓CD34的表達(dá)陽性率，比較ALL和AML患者CD34表達(dá)的差異。觀察AL患者臨床特征與療效，比較CD34表達(dá)與非CD34表達(dá)患者臨床表現(xiàn)差異和治療效果。 結(jié)果1.85例ALL患兒CD34陽性率為43.52%，42例AML患兒CD34陽性率為47.61%，AML組CD34表達(dá)略高于ALL組(P0．05)，但無統(tǒng)計(jì)學(xué)差異。2..CD34在AML-M3亞型中為低表達(dá)或不表達(dá)，有統(tǒng)計(jì)學(xué)意義；CD34在ALL-L3型中為低表達(dá)，，但統(tǒng)計(jì)學(xué)分析無意義。3.在AL預(yù)后因素分析中，CD34的陽性表達(dá)率與性別、外周血白細(xì)胞計(jì)數(shù)、血紅蛋白濃度、血小板數(shù)量等無明顯差異；但在ALL患兒中腫瘤浸潤(rùn)(肝脾、淋巴結(jié)腫大)表現(xiàn)上有統(tǒng)計(jì)學(xué)差異（X2=3.99，P=0.046），而在AML中肝脾淋巴結(jié)腫大等征象上均無明顯差異。4.含CD34的表達(dá)的ALL在誘導(dǎo)治療4周的緩解率上無統(tǒng)計(jì)學(xué)差異（P0.05）；AML患兒在誘導(dǎo)化療療效方面，CD34+組完全緩解率為35.0%，明顯低于CD34-組的72.72%（X2=6.019，P=0.014）,5.AML細(xì)胞CD34的過度表達(dá)是AML預(yù)后不良因素之一。 結(jié)論AML患者骨髓細(xì)胞CD34表達(dá)略高于ALL組。CD34在AML-M3亞型中為低表達(dá)或不表達(dá)；AML組CD34的表達(dá)與性別、外周血白細(xì)胞數(shù)、血紅蛋白濃度、血小板數(shù)量及腫瘤浸潤(rùn)(肝脾，淋巴結(jié)腫大)等表現(xiàn)上無相關(guān)性；其在誘導(dǎo)4周化療后完全緩解率上與CD34抗原表達(dá)陰性者相比有統(tǒng)計(jì)學(xué)意義。CD34在ALL-L3型中表達(dá)較其他亞型低，ALL組CD34表達(dá)與性別、外周血白細(xì)胞數(shù)、血紅蛋白濃度、血小板數(shù)量等無明顯相關(guān)性；但肝脾，淋巴結(jié)腫大等腫瘤浸潤(rùn)等臨床征象上有統(tǒng)計(jì)學(xué)差異；而在誘導(dǎo)治療4周的緩解率上差異無明顯相關(guān)性。CD34抗原表達(dá)可能是AML的一個(gè)預(yù)后不良因素。
[Abstract]:Objective to investigate the expression of CD34 antigen in children with acute leukemia. Methods the positive rates of bone marrow CD34 expression in 85 cases of acute lymphoblastic leukemia (ALL) and 42 cases of acute myeloid leukemia (AMLL) were detected by flow cytometry. To compare the difference of CD34 expression between ALL and AML patients, to observe the clinical characteristics and curative effect of AL patients, to compare the clinical manifestations and therapeutic effects between CD34 expression and non-#en4# expression. Results 1.The positive rate of CD34 in 85 cases of ALL was 43.52%. The positive rate of CD34 in 42 cases of AML was 47.61%. The expression of CD34 was slightly higher in group A than that in group ALL (P 0.05), but there was no statistical difference in the expression of CD34 in AML-M3 subtype, but the expression of CD34 was low in ALL-L3 type. However, there was no significant difference between the positive expression rate of CD34 and sex, peripheral white blood cell count, hemoglobin concentration and platelet count in the prognostic factor analysis of AL, but there was no significant difference in tumor infiltration (liver and spleen, liver and spleen) in children with ALL. There was statistical difference in the manifestation of lymphadenopathy. There was no significant difference in the signs of hepatosplenomegaly in AML. 4. There was no significant difference in remission rate of ALL with CD34 expression in 4 weeks of induction treatment. In terms of therapeutic effect, the complete remission rate of CD34 group was 35.0, which was significantly lower than that of CD34- group (72.72%). The overexpression of CD34 in AML cells was one of the factors contributing to the poor prognosis of AML. Conclusion the expression of CD34 in bone marrow cells of AML patients is slightly higher than that in ALL group. CD34 expression and sex, peripheral white blood cell count, hemoglobin concentration, platelet count and tumor infiltration (liver and spleen) are lower or not in AML-M3 subtype. The expression of CD34 in ALL-L3 group was lower than that in other subtypes, the expression of CD34 and sex, the number of peripheral blood leukocytes, and the number of peripheral blood leukocytes in all group were significantly lower than those in other subtypes, and the complete remission rate after 4 weeks of chemotherapy was significantly higher than that in patients with negative expression of CD34 antigen, and the expression of CD34 was significantly lower in ALL-L3 type than in other subtypes. There was no significant correlation between hemoglobin concentration and platelet count, but there were statistical differences in clinical signs such as liver and spleen, lymph node enlargement and tumor infiltration. However, there was no significant correlation between the remission rate of induced therapy and 4 weeks of treatment. The expression of CD34 antigen may be a poor prognostic factor in AML.
【學(xué)位授予單位】：寧夏醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類號(hào)】：R733.71

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李建勇，夏學(xué)鳴，薛永權(quán)，鄭 琳，阮長(zhǎng)耿;CD_（34）陽性成人急性髓系白血病臨床及生物學(xué)研究[J];白血病;1996年03期

2 秘營昌,卞壽庚,薛艷萍,趙耀中,孟慶祥,郭亞林,李睿,秦鐵軍;急性髓細(xì)胞白血病免疫表型特點(diǎn)及與預(yù)后的關(guān)系[J];白血病;1997年04期

3 盧新天;;小兒急性淋巴細(xì)胞白血病中樞神經(jīng)系統(tǒng)白血病診治現(xiàn)狀[J];國外醫(yī)學(xué).輸血及血液學(xué)分冊(cè);2005年02期

4 黃婕;何璐璐;方擁軍;芮耀耀;周莉;陸勤;楊引;;兒童急性白血病免疫表型及臨床研究[J];醫(yī)學(xué)臨床研究;2008年12期

5 柏樹令,趙丹;CD34抗原的生物學(xué)特性及其臨床應(yīng)用[J];解剖科學(xué)進(jìn)展;2005年01期

6 黃正剛;吳星恒;劉峗;武志紅;;44例兒童急性淋巴細(xì)胞白血病免疫表型分析[J];江西醫(yī)藥;2008年10期

7 李和蘭;陳鈺;;急性髓系白血病CD 34和CD 38抗原表達(dá)及其臨床意義[J];臨床血液學(xué)雜志;2006年03期

8 陳潔宇,周曉軍,孟奎,吳波,陸珍鳳;CD34抗原在脂肪組織腫瘤中的表達(dá)及其病理意義[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2002年01期

9 羅燕,邱丙森;CD34抗原表達(dá)在皮膚纖維瘤和隆突性纖維肉瘤鑒別診斷中的意義[J];上海醫(yī)學(xué);2000年03期

10 劉玲;金潤(rùn)銘;;急性白血病免疫分型與臨床研究[J];實(shí)用兒科臨床雜志;2006年15期

本文編號(hào)：1589026